Nasdaq · Biotech stocks database

OBX — Obsidian Therapeutics Inc.

OBX (Obsidian Therapeutics Inc.) stock: $17.75, $1.10B market cap, $355.1M cash, $741.4M EV, $1.33B fully diluted market cap. Next expected readout: Jun-29. Lead program: OBX-115 (Tumor Skin), Phase 2. Data from Fully Diluted's biotech stocks database.

Share price

$17.75

Market cap

$1,096.5M

Cash

$355.1M

Enterprise value

$741.4M

Balance sheet

Cash	$355.1M
Debt	$0.0M
Net cash	$355.1M
Enterprise value	$741.4M
Basic shares	61.8M shares
Fully diluted shares	75.0M shares
Fully diluted market cap	$1,331.5M
Cash per share	$5.75

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading OBX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 11 - Sep 22	OBX-115	Phase 2	Tumor Skin; Metastatic Melanoma; Melanoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	OBX-115
Lead indication	Tumor Skin
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06060613	Phase 2	Recruiting	Sponsor	OBX	—	Tumor Skin; Metastatic Melanoma; Melanoma	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Obsidian Therapeutics, Inc. on ClinicalTrials.gov

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego

OBX — Obsidian Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline

Active clinical trials